Budget impact analysis of medicines: updated systematic review and implications [0.03%]
药物预算影响分析的系统综述及启示
Daniel Resende Faleiros,Juliana Álvares,Alessandra Maciel Almeida et al.
Daniel Resende Faleiros et al.
This evaluation determines whether published studies to date meet the key characteristics identified for budget impact analyses (BIA) for medicines, accomplished through a systematic review and assessment against identified key characterist...
Lisa Pont,Kristian Jansen,Margrete Aase Schaufel et al.
Lisa Pont et al.
In the end stages of life, drug treatment goals shift to symptom control and quality of life and as such changes in drug utilization are expected. The aim of this paper is to review the extent to which costs are considered in drug utilizati...
Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies [0.03%]
商业数据库和管理型保健数据库的使用率差异及对未来健康经济与跨国研究的意义
Kristina Garuolienė,Brian Godman,Jolanta Gulbinovič et al.
Kristina Garuolienė et al.
Over-the-counter medicine and dietary supplement consumption among academic youth in Poland [0.03%]
波兰学术青年的非处方药和膳食补充剂消费情况
Tomasz Bochenek,Brian Godman,Katarzyna Lipowska et al.
Tomasz Bochenek et al.
Over-the-counter (OTC) medicines and dietary supplements are increasingly popular in Poland, potentially improving but also potentially posing a threat to public health. The study goal is to characterize and assess behaviors related to use ...
The cost of managing severe hypoglycemic episodes in Type 2 diabetic patients [0.03%]
2型糖尿病患者严重低血糖发作的治疗成本分析
Pedro Almeida Laires,João Conceição,Francisco Araújo et al.
Pedro Almeida Laires et al.
Introduction: Hypoglycemia is an acute complication of diabetes that increases morbidity, mortality and disease costs. We aim to estimate healthcare resource consumption and costs associated with severe hypoglycemia using...
Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies [0.03%]
氟替卡松/沙美特罗粉吸入剂治疗慢性阻塞性肺病的经济学评价：发表的研究述评
M H Roberts,M E Borrego,A A Kharat et al.
M H Roberts et al.
This review identifies and evaluates the comprehensive reporting of peer-reviewed economic evaluations of the effectiveness of fluticasone-propionate/salmeterol combination (FSC) therapy for maintenance treatment of chronic obstructive pulm...
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review [0.03%]
非瓣膜性房颤卒中预防用新型口服抗凝药物的卫生经济学评价：系统综述及定性分析
Nicola Lucio Liberato,Monia Marchetti
Nicola Lucio Liberato
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical practice represented a major change in the treatment of non-valvular atrial fibrillation (NVAF); drugs as effective as the gold standard were available, ...
Yahya E Choonara,Lisa C du Toit,Pradeep Kumar et al.
Yahya E Choonara et al.
3D-printing (3DP) is the art and science of printing in a new dimension using 3D printers to transform 3D computer aided designs (CAD) into life-changing products. This includes the design of more effective and patient-friendly pharmaceutic...
Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments [0.03%]
适合在肿瘤学中使用EQ-5D吗？文献综述及最新研究动态概述
Matthias Schwenkglenks,Klazien Matter-Walstra
Matthias Schwenkglenks
The European Quality of Life-5 Dimensions (EQ-5D) questionnaire is widely used in oncology to generate quality of life weights (utilities). The typical purpose is to inform health economic evaluation studies. The EQ-5D is generally suitable...
Reimbursement of biosimilars in Poland: is there a link to health technology assessment? [0.03%]
波兰的生物仿制药报销与卫生技术评估有关联吗？
Dominika Neumann,Anna Jabłecka
Dominika Neumann
Introduction: Due to their complex structures, biosimilars are not generics. The differences between them are considered during market authorization processes but remain unclear during reimbursement decision-making. ...